“Five of our board members invested £5,000 each to help David build his prototype. It had what we look for in a startup – a clever, difficult-to-copy technology that had global reach. And that was the start of our 13-year journey with Touch BIonics,” Niki McKenzie, Archangels Investment Director
Read the full story on medtechengine.com
